87 related articles for article (PubMed ID: 2169785)
1. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
Tabona MV
Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
Marty M
Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
Chevallier B
Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
[TBL] [Abstract][Full Text] [Related]
4. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
Smith IE
Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
Cupissol DR; Serrou B; Caubel M
Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
7. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
9. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
Soukop M
Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
[TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
11. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
12. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
Abali H; Celik I
Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
[TBL] [Abstract][Full Text] [Related]
13. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study].
Golaszewski T; Kölbl H; Lahousen M; Staab HJ
Wien Klin Wochenschr; 1995; 107(20):613-21. PubMed ID: 7502509
[TBL] [Abstract][Full Text] [Related]
14. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
[TBL] [Abstract][Full Text] [Related]
15. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.
Blower PR
Eur J Cancer; 1990; 26 Suppl 1():S8-11. PubMed ID: 2169786
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
Hesketh PJ; Crews JR; Cohen R; Blackburn LM; Friedman CJ
Cancer J; 2000; 6(3):157-61. PubMed ID: 10882331
[TBL] [Abstract][Full Text] [Related]
17. The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
Joss RA; Brand BC; Buser KS; Cerny T
Eur J Cancer; 1990; 26 Suppl 1():S2-8. PubMed ID: 2169781
[TBL] [Abstract][Full Text] [Related]
18. [Granisetron, a new and potent antiemetic for treatment of cytostatic drug-induced vomiting in gynecological malignancies].
Regidor PA; Schindler AE
Geburtshilfe Frauenheilkd; 1994 Jan; 54(1):51-4. PubMed ID: 8150251
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
[TBL] [Abstract][Full Text] [Related]
20. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael J; Harris AL
Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
